September 25, 2014

Final Stargardt Patient Treated In Initial Stem Cell Trial

by

Final Stargardt Patient Treated In Initial Stem Cell Trial

Advanced Cell Technology (ACT) has treated the final patient in the UK-based Phase 1 clinical trial evaluating the safety and tolerability of the company’s stem cell therapy for Stargardt’s disease. To date, no adverse events have been reported. The company is working with U.S. and European regulators to commence a Phase 2 trial to assess the safety and efficacy of stem cell therapy in patients with Stargardt disease and dry age-related macular degeneration.
Read the company’s press release for more information.

We offer resources and free materials for those living with low vision.

View Resources